Brief: Immix Biopharma Completes 3rd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
16/10/2023 14:26
Oct 16 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA COMPLETES 3RD NXC-201 ENGINEERING BATCH AT
ITS
U.S. CAR-T MANUFACTURING SITE
Source text for Eikon: ID:nGNX8V7cx9
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary